Rivaroxaban Market (Updated Version Available)

The report offers detailed coverage of Rivaroxaban industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Rivaroxaban by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
Bayer is the only supplier of Rivaroxaban enjoying production market share100% in 2015 and it will still in this situation until 2023.

The report forecast global Rivaroxaban market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2027.

First, this report covers the present status and the future prospects of the global Rivaroxaban market for 2015-2027.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

Key Companies
Bayer
J&J

At the same time, we classify Rivaroxaban according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market Segment as follows:
Market by Order Type
2.5 mg
10 mg
15 mg
20 mg
Market by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)

By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Rivaroxaban market for the forecast period 2021 - 2027?
• What are the driving forces in the Rivaroxaban market for the forecast period 2021 - 2027?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Rivaroxaban industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?